Q-omics provides the consensus-scored PYROXD1 profile across patient tissues and cancer cell-line models. PYROXD1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PYROXD1 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, PYROXD1 RNA expression shows 18,033 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where PYROXD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PYROXD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PYROXD1 survival associations across molecular data types. PYROXD1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PYROXD1 RNA expression–survival associations across cancer types. High PYROXD1 expression shows unfavorable associations in UVM, LGG and UCEC, but favorable associations in KIRC, SKCM and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PYROXD1 RNA expression.
This table summarizes PYROXD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PYROXD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PYROXD1 shows lower tumor expression in THCA, COAD, KICH and KIRP and higher tumor expression in LIHC and CHOL. The THCA box plot shows higher PYROXD1 RNA expression in normal versus tumor tissue (log2 FC = −0.342, t-test p < 0.001).
This table shows molecular features associated with PYROXD1 in patient tissues and cancer cell lines. In patient samples, PYROXD1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PYROXD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SKIN.
